Financial Survey: Finch Therapeutics Group (NASDAQ:FNCH) and LadRx (OTCMKTS:CYTR)

Valuation & Earnings

This table compares Finch Therapeutics Group and LadRx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75 million	($8.82)	-1.39
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Finch Therapeutics Group and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
LadRx	N/A	-67.61%	-45.39%

Insider & Institutional Ownership

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 0.1% of LadRx shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 12.8% of LadRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Finch Therapeutics Group has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500.

Summary

LadRx beats Finch Therapeutics Group on 5 of the 8 factors compared between the two stocks.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.